Reviewer’s report

Title: Association of serum C1q/TNF-related protein-3 (CTRP-3) in patients with coronary artery disease

Version: 0 Date: 15 Jun 2017

Reviewer: Francesco Vieceli Dalla Sega

Reviewer’s report:

This a study on the association of serum CTRP-3 and CAD.

Findings reported are in contrast with published data showing a decrease of CTRP-3 in CAD patients (Fedaei et al. 2016). Authors suggest that the CTRP-3 levels increase in CAD patients could be a "defensive response" but this not explain why other studies found opposite results (CAD patients having lower levels of CTRP-3).

Since CTRP 3 levels are influenced by lipids and glucose metabolism and they are related to conditions like diabetes and obesity cholesterol-lowering drugs and hypoglycemic drugs should be necessarily taken into account.

Clinical characteristics should be shown for all the CAD subgroups.

The ELISA assay used should be described.

In the title it is not necessary specify that the study is "in humans".

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal